Filtered By:
Condition: Heart Failure
Therapy: Dialysis
This page shows you your search results in order of date. This is page number 4.
Order by Relevance | Date
Total 251 results found since Jan 2013.
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Medicina (Kaunas). 2023 Feb 16;59(2):388. doi: 10.3390/medicina59020388.ABSTRACTSodium glucose cotransporter 2 inhibitor (SGLT2i) is a class of drugs that were originally intended for decreasing blood glucose in diabetes. However, recent trials have shown that there are other beneficial effects. Major clinical trials involving SGLT2i medications from 2015 to 2022 were reviewed using PUBMED search. Recent major SGLT2i landmark trials have demonstrated benefits for cardiovascular disease (reduce major adverse cardiovascular events (heart attack, stroke, cardiovascular death), hospitalization for heart failure, all-cause deat...
Source: Medicina (Kaunas) - February 25, 2023 Category: Universities & Medical Training Authors: Jonathan C H Chan Michael C Y Chan Source Type: research
Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
ConclusionThere was no evidence of increased risk of cardiovascular events or mortality with roxadustat compared with ESA in patients with anemia who have NDD or ID-DD CKD. Although TEAEs occurred commonly in both the roxadustat and ESA groups, patients infrequently discontinued the study drug because of an adverse event.Clinical Trial Registration NumbersDOLOMITES, 1517-CL-0610 [NCT02021318]; HIMALAYAS, FGCL-4592-063 [NCT02052310]; SIERRAS, FGCL-4592-064 [NCT02273726]; and ROCKIES, D5740C00002 [NCT02174731].
Source: Advances in Therapy - February 7, 2023 Category: Drugs & Pharmacology Source Type: research
Pitavastatin Compared with Differential Intervention Trial by Standard Therapy on Cardiovascular Events in Patients with Dyslipidemia on Chronic Hemodialysis (DIALYSIS): A Randomized Controlled Trial
Conclusion: Our study has demonstrated that aggressive intervention with pitavastatin is more effective than the standard (dietary) therapy for improving the clinical outcomes in patients with dyslipidemia on chronic hemodialysis.Blood Purif
Source: Blood Purification - January 30, 2023 Category: Hematology Source Type: research
Clinical Features and Risk Factors of Mortality in Patients with Posterior Reversible Encephalopathy Syndrome
CONCLUSIONS: Our results indicate that PRES could be considered as a sign of a very high-risk patient. We also demonstrated that heart failure and stroke were independent risk factors for death in patients with PRES; moreover, pregnancy was a protective factor.PMID:36419591 | PMC:PMC9678458 | DOI:10.1155/2022/9401661
Source: Behavioural Neurology - November 24, 2022 Category: Neurology Authors: Hong-Wei Cui Ru-Yi Lei Bo-Ai Zhang Source Type: research
